about
Leptin: a possible link between food intake, energy expenditure, and reproductive function.Adipokines and sexual hormones associated with the components of the metabolic syndrome in pharmacologically untreated subjects: data from the brisighella heart study.Phaseolus vulgaris extract affects glycometabolic and appetite control in healthy human subjects.Hormonal control of the neuropeptide Y system.Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients.Theranostic Nanocages for Imaging and Photothermal Therapy of Prostate Cancer Cells by Active Targeting of Neuropeptide-Y Receptor.Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer.Hypothalamic neuropeptide systems as targets for potential anti-obesity drugs.Relevance of the neuropeptide Y system in the biology of cancer progression.Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer.Feeding behavior in mammals including humans.Leptin, ciliary neurotrophic factor, leukemia inhibitory factor and interleukin-6: class-I cytokines involved in the neuroendocrine regulation of the reproductive function.Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression.Adiponectin interactions in bone and cartilage biology and disease.Statin therapy and related risk of new-onset type 2 diabetes mellitus.Risk identification and possible countermeasures for muscle adverse effects during statin therapy.Changes in stress hormones and metabolism during a 105-day simulated Mars mission.Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases.Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial.GC-MS profiling of the phytochemical constituents of the oleoresin from Copaifera langsdorffii Desf. and a preliminary in vivo evaluation of its antipsoriatic effect.Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.The natural antioxidant alpha-lipoic acid induces p27(Kip1)-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells.Regulation of prostate cancer cell proliferation by somatostatin receptor activation.Cholinergic regulation of neuropeptide Y synthesis and release in human neuroblastoma cells.Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells.Expression of functional ciliary neurotrophic factor receptors in immortalized gonadotrophin-releasing hormone-secreting neurones.Increased circulating adiponectin in males with chronic HCV hepatitis.Cholinergic muscarinic mechanisms regulate neuropeptide Y gene expression via protein kinase C in human neuroblastoma cells.Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue.In vitro chronic administration of ERbeta selective ligands and prostate cancer cell growth: hypotheses on the selective role of 3beta-adiol in AR-positive RV1 cells.Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus.Free and bound leptin in prepubertal children with Down's syndrome and different degrees of adiposity.Free and bound plasma leptin in normal weight and obese men and women: relationship with body composition, resting energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference.Dietary iron overload induces visceral adipose tissue insulin resistance.The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways.
P50
Q34056731-E8229EF7-DDB8-4F2B-81FF-B40CBAECB63CQ34082707-A0B39F33-5282-4264-B50F-3F6AF2B8477CQ34304732-E53E9620-0493-4E12-9D14-C507307C7E50Q35061220-D235B2D1-3AA2-4F03-832A-2025A87F0838Q35665099-6AA2B54C-8D73-4D03-9CF6-50B0F9CC4CF6Q35837412-122E83AB-A33B-43AB-9974-15B9BDA3906BQ36181179-D3DAFA7A-29CD-4E05-966A-D177EAE12654Q36362512-955D165A-B65F-431E-9A27-19F8FB711124Q36574008-7C14E563-AF93-4596-AB4F-F58EBCEBE038Q36699622-56436DED-9D3B-41BC-AD4E-3A2FD795F753Q36724142-D2B528E3-7C16-48C6-967F-9137713949F0Q36990444-28EB7EBC-FE76-4B9B-87B9-67933097CB12Q37008398-8C4C9A17-3126-43F5-B27A-9F664D184DB9Q37490072-9B575091-11B1-408A-904E-37F6EE8BCC92Q37596466-B787A738-08AC-4D07-97D7-3BA20D39F46FQ38039201-85A68D4F-18D8-4028-BA63-4CF0FCF6D1A7Q38047142-1A77F021-D394-4ABC-BBD3-AF36DEF7D12DQ38200774-CCA8D5AE-B57D-4D06-8718-CE41596A89AEQ38340054-7950DF70-5DCD-405E-8DB2-A526C05A3D45Q38447776-430A5EC4-8736-4BFC-8EAA-72954A1A1A93Q38627989-0490B186-9BC6-41DB-AF7C-B57E0D52B278Q38728349-6CF8548E-0F20-4322-8D76-74C2D204C1AFQ39065274-1CE9B3EF-D224-425D-B6ED-6333D8F0D33FQ39273397-A1D25465-EAA0-4BF5-A997-CC0AAB48871DQ39287284-D42666CD-66C0-48CB-8D9A-AC8BF38DAF76Q39650818-0D4A7C74-FDB2-47AC-8289-A59F5CB91A6AQ39687994-D0ED3347-694E-4BD3-8A2A-237588995E25Q39771837-778EA545-E6D0-468C-BB1C-D6C6CB27CBD8Q40031723-9EB85AA4-1329-438E-9F2A-4E699C466EB8Q40341691-93F28840-D14D-4058-A1CC-3DBFBC9C6C9CQ40427316-221056E6-8981-4D1A-81C9-9A33B1D6E595Q40621871-87D1A495-681B-4D77-B474-4806709BF3B6Q41024960-A9CCAFEF-1405-48BE-B64A-E81CCFE6CA10Q41060579-1168E09D-3AF0-47FA-9776-663F33690836Q42573768-EB64A83C-2526-4114-B1C0-2B4B622B9B87Q44232646-325D91EC-94D0-40DF-98A4-0D59FFA274A9Q44909881-88C1C175-F052-4D33-B958-5DCC46D21C59Q45237933-05642C72-5CDB-43ED-AAC2-D9913E043A57Q45907556-697B9129-6F8F-4BF5-9B2C-83355B4D9F9DQ45924750-E2DEF9C9-07CC-4348-88AE-BCC8D7764ED2
P50
description
researcher
@en
wetenschapper
@nl
name
P Magni
@en
P Magni
@nl
type
label
P Magni
@en
P Magni
@nl
prefLabel
P Magni
@en
P Magni
@nl
P106
P31
P496
0000-0002-2254-8881